EMA and FDA set common principles for AI in medicine development
EMA, FDI, Medicinal Products, Artificial Intelligence Elisabethann Wright EMA, FDI, Medicinal Products, Artificial Intelligence Elisabethann Wright

EMA and FDA set common principles for AI in medicine development

The European Medicines Agency (EMA) and the US FDA have jointly developed ten principles for good Artificial Intelligence (AI) practice in life cycle management for medicinal products.

The purpose of these principles is to permit AI used in the development of medicinal products to be

Read More
Commission publishes Guidelines on the definition of an artificial intelligence system established by the AI Act